Log in

Stemline Therapeutics Stock Price, News & Analysis (NASDAQ:STML)

$9.02
-0.02 (-0.22 %)
(As of 10/18/2019 03:00 AM ET)
Today's Range
$8.90
Now: $9.02
$9.32
50-Day Range
$8.59
MA: $10.51
$12.48
52-Week Range
$7.82
Now: $9.02
$18.22
Volume426,600 shs
Average Volume629,124 shs
Market Capitalization$396.48 million
P/E RatioN/A
Dividend YieldN/A
Beta1.41
Stemline Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of oncology therapeutics in the United States and internationally. The company offers ELZONRIS, a targeted therapy directed to the interleukin-3 receptor (CD123) for patients with blastic plasmacytoid dendritic cell neoplasm in adults, and in pediatric patients two years and older. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:STML
CUSIPN/A
Phone646-502-2311

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$500,000.00
Book Value$1.32 per share

Profitability

Net Income$-85,020,000.00

Miscellaneous

Employees92
Market Cap$396.48 million
Next Earnings Date11/14/2019 (Estimated)
OptionableOptionable

Receive STML News and Ratings via Email

Sign-up to receive the latest news and ratings for STML and its competitors with MarketBeat's FREE daily newsletter.


Stemline Therapeutics (NASDAQ:STML) Frequently Asked Questions

What is Stemline Therapeutics' stock symbol?

Stemline Therapeutics trades on the NASDAQ under the ticker symbol "STML."

How were Stemline Therapeutics' earnings last quarter?

Stemline Therapeutics Inc (NASDAQ:STML) posted its quarterly earnings data on Friday, August, 2nd. The biopharmaceutical company reported ($0.42) EPS for the quarter, topping analysts' consensus estimates of ($0.47) by $0.05. The biopharmaceutical company earned $13.01 million during the quarter, compared to analyst estimates of $8.84 million. View Stemline Therapeutics' Earnings History.

When is Stemline Therapeutics' next earnings date?

Stemline Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, November 14th 2019. View Earnings Estimates for Stemline Therapeutics.

What price target have analysts set for STML?

6 brokerages have issued 1 year price objectives for Stemline Therapeutics' stock. Their forecasts range from $17.00 to $35.00. On average, they expect Stemline Therapeutics' stock price to reach $25.20 in the next year. This suggests a possible upside of 179.4% from the stock's current price. View Analyst Price Targets for Stemline Therapeutics.

What is the consensus analysts' recommendation for Stemline Therapeutics?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Stemline Therapeutics in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Stemline Therapeutics.

What are Wall Street analysts saying about Stemline Therapeutics stock?

Here are some recent quotes from research analysts about Stemline Therapeutics stock:
  • 1. According to Zacks Investment Research, "Stemline Therapeutics, Inc. is a biopharmaceutical company developing oncology therapeutics that target cancer stem cells and tumor bulk. The company is developing SL-401, a biologic-drug conjugate, for relapsed or refractory acute myeloid leukemia; and SL-701, a synthetic peptide vaccine, for pediatric and adult high-grade gliomas. Stemline Therapeutics, Inc. is based in New York. " (8/7/2019)
  • 2. HC Wainwright analysts commented, "Our 12-month price target is derived from a discounted cash flow based asset value of $1.46B for 15% discount rate and 2% terminal growth rate. The company has approximately 42M shares outstanding after the recent financing. Probabilities of market entry ascribed to SL-401 and SL-701 are 100% and 45%, respectively." (1/25/2019)

Has Stemline Therapeutics been receiving favorable news coverage?

News coverage about STML stock has been trending somewhat negative on Friday, InfoTrie Sentiment Analysis reports. InfoTrie ranks the sentiment of media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Stemline Therapeutics earned a media sentiment score of -1.9 on InfoTrie's scale. They also assigned media stories about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the stock's share price in the near future. View News Stories for Stemline Therapeutics.

Are investors shorting Stemline Therapeutics?

Stemline Therapeutics saw a increase in short interest in the month of September. As of September 30th, there was short interest totalling 6,130,000 shares, an increase of 24.6% from the August 30th total of 4,920,000 shares. Based on an average trading volume of 620,300 shares, the short-interest ratio is currently 9.9 days. Approximately 15.2% of the shares of the company are short sold. View Stemline Therapeutics' Current Options Chain.

Who are some of Stemline Therapeutics' key competitors?

What other stocks do shareholders of Stemline Therapeutics own?

Who are Stemline Therapeutics' key executives?

Stemline Therapeutics' management team includes the folowing people:
  • Dr. Ivan Bergstein, Founder, Pres, CEO & Chairman (Age 53)
  • Mr. David G. Gionco, VP of Fin. & Chief Accounting Officer (Age 59)
  • Mr. Kenneth Hoberman, COO & Corp. Sec. (Age 54)
  • Mr. Robert Francomano, Sr. VP & Global Head of Commercial
  • Mr. John A. Salvagno, Sr. VP of Quality & Operations

Who are Stemline Therapeutics' major shareholders?

Stemline Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional investors include Rhenman & Partners Asset Management AB (1.16%). Company insiders that own Stemline Therapeutics stock include David Gionco, Ivan Bergstein and Kenneth Hoberman. View Institutional Ownership Trends for Stemline Therapeutics.

Which major investors are buying Stemline Therapeutics stock?

STML stock was purchased by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB. View Insider Buying and Selling for Stemline Therapeutics.

How do I buy shares of Stemline Therapeutics?

Shares of STML can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Stemline Therapeutics' stock price today?

One share of STML stock can currently be purchased for approximately $9.02.

How big of a company is Stemline Therapeutics?

Stemline Therapeutics has a market capitalization of $396.48 million and generates $500,000.00 in revenue each year. The biopharmaceutical company earns $-85,020,000.00 in net income (profit) each year or ($2.99) on an earnings per share basis. Stemline Therapeutics employs 92 workers across the globe.View Additional Information About Stemline Therapeutics.

What is Stemline Therapeutics' official website?

The official website for Stemline Therapeutics is http://www.stemline.com/.

How can I contact Stemline Therapeutics?

Stemline Therapeutics' mailing address is 750 LEXINGTON AVENUE ELEVENTH FLOOR, NEW YORK NY, 10022. The biopharmaceutical company can be reached via phone at 646-502-2311 or via email at [email protected]


MarketBeat Community Rating for Stemline Therapeutics (NASDAQ STML)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  394 (Vote Outperform)
Underperform Votes:  217 (Vote Underperform)
Total Votes:  611
MarketBeat's community ratings are surveys of what our community members think about Stemline Therapeutics and other stocks. Vote "Outperform" if you believe STML will outperform the S&P 500 over the long term. Vote "Underperform" if you believe STML will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/18/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel